Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial

Article ID	Journal	Published Year	Pages	File Type
8442755	European Journal of Cancer	2014	12 Pages	PDF

Abstract

F. Hoffmann-La Roche Ltd, the Netherlands.

Keywords

Phase 2 trial bevacizumab Metastatic breast cancer Paclitaxel Capecitabine

Related Topics

Life Sciences Biochemistry, Genetics and Molecular Biology Cancer Research

Preview

Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial

Authors

S.W. Lam, S.M. de Groot, A.H. Honkoop, A. Jager, A.J. ten Tije, M.M.E.M. Bos, S.C. Linn, J. van den Bosch, J.R. Kroep, J.J. Braun, H. van Tinteren, E. Boven, Dutch Breast Cancer Research Group (BOOG) Dutch Breast Cancer Research Group (BOOG),